Skip to main content

Urology

Promising early results for cancer vaccine in RCC

A neoantigen-targeting personalized cancer vaccine has shown promising antitumor activity in people with high-risk, fully resected renal cell carcinoma.

Read more

Editor's Choice

Sexual wellbeing and intimacy in IBD

Sexual dysfunction is common in people with IBD, but what is the best way to approach it? Get practical advice on how to have conversations with patients, assessment, identification of contributory factors, management, and more.

New approaches to treat kidney injury after cardiac surgery

Post-surgical acute kidney injury is common after cardiac procedures. Despite some understanding of the mechanisms, there remains no effective treatment for prevention or management. Might the new therapies in early clinical trials be the solution?

How do you identify children with cancer predisposition syndromes?

CPS are genetic disorders that significantly increase the risk of developing malignancies. The malignant features of CPS are well-studied, but recognizing their non-malignant features is crucial for early diagnosis in children and adolescents.

Rare complication in a patient with seminoma

A patient treated with carboplatin for stage I seminoma developed hematuria and acute kidney injury. It is crucial to recognize this rare but serious complication and start treatment promptly to prevent further kidney damage.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Case-based insights: Oncology and hematology (Link opens in a new window)


Refresh your knowledge in oncology and hematology: 

  • 45 clinical cases across different topics with relevant clinical images
  • Written by renowned experts 
  • Knowledge-check questions with answers
Try the first set of cases now

ctDNA and bladder cancer: Current understanding and beyond

Urologist James Catto asks oncologist Thomas Powles key questions on the role of ctDNA in the understanding of urothelial cancer and its potential to improve treatment decision-making in the future.

Supported by:
  • F. Hoffmann-La Roche Ltd.
Prof. Thomas Powles
Prof. James Catto
Developed by: Springer Healthcare
Watch now

Case Studies

Rare complication in a patient with seminoma

A patient treated with carboplatin for stage I seminoma developed hematuria and acute kidney injury. It is crucial to recognize this rare but serious complication and start treatment promptly to prevent further kidney damage.

Atypical presentation of PJP

Typical symptoms of Pneumocystis jirovecii pneumonia include dyspnea, cough, and low-grade fever. But this patient, an allogeneic stem cell transplant recipient, presented with hypercalcemia and kidney injury.

Hypertension and hypokalemia with severe hydronephrosis

A case of suspected primary aldosteronism that was complicated to diagnose because severe hydronephrosis meant the patient's aldosterone-to-renin ratio values were normal.

Current Reviews

The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer

Prostate-specific membrane antigen (PSMA) is overexpressed in nearly 90% of prostate cancer (PCa), especially in later-stage metastatic castration disease (mCRPC) [ 1 – 3 ].

The lived experience of active surveillance for prostate cancer: a systematic review and meta-synthesis

Prostate cancer is one of the most prevalent cancers to impact men, with almost 1.5 million men diagnosed in 2022 [ 1 ]. Globally, cancer is estimated to cost $25.2 trillion in international dollars between 2020 and 2050 [ 2 ]; prostate cancer …

Cell-free Tumor DNA: a Promising Technology for Diagnosis, Surveillance and Therapeutic Decision in Urothelial Carcinoma of the Bladder

Urothelial carcinoma of the bladder is the 10th most prevalent cancer worldwide. [ 1 , 2 ]. It is considered one of the most costly oncological diseases due to its improved survival rates and the necessity for lifelong surveillance [ 1 , 2 ]. The …

Patients’ Perceptions of Stress Urinary Incontinence Treatment: A Scoping Review of Qualitative Studies

There are many different available treatment options for stress urinary incontinence (SUI), ranging from expectant management to surgery. They are often offered in a stepped-care approach. Each of these treatments has been studied extensively and …

CME & eLearning

eLearning (Link opens in a new window)

The evolving landscape of metastatic urothelial carcinoma brings with it many challenges, such as optimally sequencing therapies and managing adverse events. Navigate your way through these with the Ultimate mUC challenge game and expert-to-expert interviews.

Supported by:
  • Merck Healthcare KGaA, Darmstadt, Germany and Astellas
Developed by: Springer Healthcare IME

Further Reading

The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer

Prostate-specific membrane antigen (PSMA) is overexpressed in nearly 90% of prostate cancer (PCa), especially in later-stage metastatic castration disease (mCRPC) [ 1 – 3 ].

The lived experience of active surveillance for prostate cancer: a systematic review and meta-synthesis

Prostate cancer is one of the most prevalent cancers to impact men, with almost 1.5 million men diagnosed in 2022 [ 1 ]. Globally, cancer is estimated to cost $25.2 trillion in international dollars between 2020 and 2050 [ 2 ]; prostate cancer …

Prospective observational study on the relationships between genetic alterations and survival in Japanese patients with metastatic castration-sensitive prostate cancer: the impact of IDC-P

Intraductal carcinoma of the prostate (IDC-P) is a high-grade, high-volume, invasive prostate cancer (PCa) with poor clinical outcomes; it manifests as well-circumscribed lesions with intact basal cells lining distended ducts infiltrated by …

Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification

Combination treatment involving an immune checkpoint inhibitor (ICI) is the standard-of-care first-line (1L) treatment for patients with advanced renal cell carcinoma (aRCC) [ 1 – 3 ]. The International Metastatic RCC Database Consortium (IMDC) …